RLYB
Rallybio Corporation
NASDAQ · USHealthcareBiotechnology
$16.71+1.77%
Price as of Jul 20, 2026
RLYB profitability
Rallybio Corporation profitability
Margins, returns on capital and operating-efficiency metrics from the latest trailing period.
Margins
- Gross margin
- -1517.1%
- EBITDA margin
- -3270.4%
- EBIT margin
- -3278.2%
- Net margin
- -911.1%
- Free cash flow margin
- -3215.2%
Returns
- Return on equity
- -15.5%
- Return on assets
- -14.4%
- Return on invested capital
- -55.8%
- Asset turnover
- 0.01x
Cash efficiency
- Cash from operations
- -$27.6M
- Cash per share
- $8.83
Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.